These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12143433)

  • 1. Variability in hemoglobin levels: clinical implications. Case study of the anemic patient.
    Candela JM; Dutka P; Bennett J; Holland M; Donahue C; Delorme J; Lynn R
    Nephrol Nurs J; 2001 Oct; 28(5):567-70. PubMed ID: 12143433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A; Covic A; Locatelli F; Macdougall IC;
    Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E; Ofsthun N; Lazarus JM
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemoglobin variability in epoetin-treated hemodialysis patients.
    Berns JS; Elzein H; Lynn RI; Fishbane S; Meisels IS; Deoreo PB
    Kidney Int; 2003 Oct; 64(4):1514-21. PubMed ID: 12969173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between hemoglobin and hematocrit levels and hospitalization and survival rates in dialysis patients.
    Brattich M
    Nephrol Nurs J; 2003 Apr; 30(2):231-4. PubMed ID: 12737001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of computer-assisted European Best Practice Guideline implementation on adherence and target attainment: ORAMA results.
    Locatelli F; Covic A; Macdougall IC; Scherhag A; Wiecek A;
    J Nephrol; 2009; 22(5):662-74. PubMed ID: 19810000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient.
    MacCracken MA
    Nephrol Nurs J; 2001 Aug; 28(4):435-8. PubMed ID: 12143466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
    Breiterman-White R
    Nephrol Nurs J; 2006; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia in CKD: prevalence, diagnosis, and treatment. Case study of the anemic patient.
    Kammerer J; Ratican M; Elzein H; Mapes D
    Nephrol Nurs J; 2002 Aug; 29(4):371-4. PubMed ID: 12224371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
    Locatelli F; Covic A; Macdougall IC; Wiecek A;
    J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
    Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
    Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K; Moran J; Hlatky M; Lafayette R
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
    Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.